RA
JNCE

Royce & Associates’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Royce & Associates’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,699
Closed -$18K – 1218
2018
Q3 		$18K Buy
2,699
+1,321
+96% +$9.82K ﹤0.01% 1160
2018
Q2 		$11K Buy
+1,378
New +$19.9K ﹤0.01% 1199
2018
Q1 		– Sell
-588
Closed -$7K – 1292
2017
Q4 		$7K Buy
588
+82
+16% +$1.21K ﹤0.01% 1224
2017
Q3 		$8K Buy
+506
New +$7.15K ﹤0.01% 1197

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royce & Associates's JNCE Position: Q4 2018 in Review

Royce & Associates sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2018, closing a stake of 2,699 shares — an estimated $18K sold.

Royce & Associates first reported a position in JNCE in Q3 2017 and held it in 4 quarters. The position peaked at $18K in Q3 2018. 84 funds tracked by Wall St. Rank hold JNCE as of Q4 2018.

  • Royce & Associates reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Royce & Associates sold 2,699 Jounce Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $18K.
  • Royce & Associates first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
  • Royce & Associates's Jounce Therapeutics, Inc. Common Stock position peaked at $18K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Royce & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.